For individuals who either live with or are at risk of contracting HIV, a medication that provides both (partial) treatment of HIV symptoms and pre-exposure prophylaxis (PrEP) against getting the ...

When its U.S. patent cliff for HIV med Truvada was still on the horizon, Gilead Sciences won approval for follow-up med Descovy and launched an aggressive campaign to switch patients to the new drug.

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen during the outbreak of the coronavirus disease (COVID-19), in ...

The rising cost of Gilead’s Truvada may be a key factor in why the HIV prevention drug has not been widely used, according to an analysis published in the Annals of Internal Medicine. Truvada, also ...

Descovy demonstrated continued noninferiority to Truvada for HIV pre-exposure prophylaxis and statistically significant differences over Truvada for pre-specified secondary end points. In the phase 3, ...

Consumer Reports has no financial relationship with advertisers on this site. About 38,000 Americans develop HIV each year, according to the Centers for Disease Control and Prevention. Two ...

COLUMBUS (WCMH) — Life saving for those living with HIV, disease preventing for those at high risk for contracting it, a dual use drug that both treats and prevents HIV is at the center of multiple ...

Editor’s Note: This is the second part of a two-part series on PrEP. Ask a group of gay men what they think of Truvada, and you’re likely to get a response that goes something like this: “I don’t like ...

A long-awaited generic version of Truvada, used for both HIV treatment and PrEP, went on the market Friday, October 2. But the wholesale cost of the new pill from Teva Pharmaceuticals – about $1,455 – ...

Gilead Sciences will give free Truvada pills to 200,000 uninsured people for the next 11 years to help prevent new HIV infections, the pharmaceutical company said Thursday. The announcement of the ...

A Food and Drug Administration (FDA) panel is debating whether to make history by recommending approval of the first drug to prevent HIV infection. The advisory committee is expected to vote on ...